{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:16:45Z","timestamp":1793146605082,"version":"4.5.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["KOPP16I0, PARTID18P0, MCCOY19RO"],"award-info":[{"award-number":["KOPP16I0, PARTID18P0, MCCOY19RO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL158747, R01HL148171, R01AI24121, R01HL127651"],"award-info":[{"award-number":["R01HL158747, R01HL148171, R01AI24121, R01HL127651"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,9,16]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Abnormal macrophage function caused by dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) is a critical contributor to chronic airway infections and inflammation in people with cystic fibrosis (PWCF). Elexacaftor\/tezacaftor\/ivacaftor (ETI) is a new CFTR modulator therapy for PWCF. Host\u2013pathogen and clinical responses to CFTR modulators are poorly described. We sought to determine how ETI impacts macrophage CFTR function, resulting effector functions and relationships to clinical outcome changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical information and\/or biospecimens were obtained at ETI initiation and 3, 6, 9 and 12\u2005months post-ETI in 56 PWCF and compared with non-CF controls. Peripheral blood monocyte-derived macrophages (MDMs) were isolated and functional assays performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ETI treatment was associated with increased CF MDM CFTR expression, function and localisation to the plasma membrane. CF MDM phagocytosis, intracellular killing of CF pathogens and efferocytosis of apoptotic neutrophils were partially restored by ETI, but inflammatory cytokine production remained unchanged. Clinical outcomes including increased forced expiratory volume in 1\u2005s (+10%) and body mass index (+1.0\u2005kg\u00b7m<jats:sup>\u22122<\/jats:sup>) showed fluctuations over time and were highly individualised. Significant correlations between post-ETI MDM CFTR function and sweat chloride levels were observed. However, MDM CFTR function correlated with clinical outcomes better than sweat chloride.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ETI is associated with unique changes in innate immune function and clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.02861-2021","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T14:36:00Z","timestamp":1666276560000},"page":"2102861","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1183","volume":"61","author":[{"given":"Shuzhong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra L.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-9194","authenticated-orcid":false,"given":"Frank","family":"Robledo-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Jaganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevian","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal O.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanne","family":"Hall-Stoodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Partida-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2024102103070625000_61.4.2102861.1","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024102103070625000_61.4.2102861.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024102103070625000_61.4.2102861.3","doi-asserted-by":"crossref","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102103070625000_61.4.2102861.4","doi-asserted-by":"crossref","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"2024102103070625000_61.4.2102861.5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024102103070625000_61.4.2102861.6","doi-asserted-by":"publisher","DOI":"10.4161\/auto.7.11.17660"},{"key":"2024102103070625000_61.4.2102861.7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jcf.2018.10.010","article-title":"AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function","volume":"18","author":"Assani","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024102103070625000_61.4.2102861.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502609"},{"key":"2024102103070625000_61.4.2102861.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096681"},{"key":"2024102103070625000_61.4.2102861.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186169"},{"key":"2024102103070625000_61.4.2102861.11","doi-asserted-by":"publisher","DOI":"10.1159\/000446825"},{"key":"2024102103070625000_61.4.2102861.12","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Lara-Reyna","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"2024102103070625000_61.4.2102861.13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/JLB.4RU0620-245R","article-title":"Macrophage dysfunction in cystic fibrosis: nature or nurture?","volume":"109","author":"Turton","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2024102103070625000_61.4.2102861.14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3389\/fimmu.2020.01871","article-title":"Consequences of CRISPR-Cas9-mediated CFTR knockout in human macrophages","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2024102103070625000_61.4.2102861.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67729-5"},{"key":"2024102103070625000_61.4.2102861.16","doi-asserted-by":"publisher","DOI":"10.1002\/0471142735.im0723s111"},{"key":"2024102103070625000_61.4.2102861.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202004-0991OC"},{"key":"2024102103070625000_61.4.2102861.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22558-5"},{"key":"2024102103070625000_61.4.2102861.19","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0502OC"},{"key":"2024102103070625000_61.4.2102861.20","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1038\/s41598-017-11012-7","article-title":"Ezrin links CFTR to TLR4 signaling to orchestrate anti-bacterial immune response in macrophages","volume":"7","author":"Di Pietro","year":"2017","journal-title":"Sci Rep"},{"key":"2024102103070625000_61.4.2102861.21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jaci.2018.10.046","article-title":"Transcriptional and functional diversity of human macrophage repolarization","volume":"143","author":"Gharib","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103070625000_61.4.2102861.22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jcf.2018.07.012","article-title":"Differential expression of genes and receptors in monocytes from patients with cystic fibrosis","volume":"18","author":"Tarique","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024102103070625000_61.4.2102861.23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcf.2017.03.011","article-title":"CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis","volume":"16","author":"Tarique","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2024102103070625000_61.4.2102861.24","doi-asserted-by":"crossref","first-page":"21700","DOI":"10.1038\/s41598-020-78817-x","article-title":"(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages","volume":"10","author":"Shrestha","year":"2020","journal-title":"Sci Rep"},{"key":"2024102103070625000_61.4.2102861.25","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2016.1217370"},{"key":"2024102103070625000_61.4.2102861.26","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0412188"},{"key":"2024102103070625000_61.4.2102861.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019970"},{"key":"2024102103070625000_61.4.2102861.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022212"},{"key":"2024102103070625000_61.4.2102861.29","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1009655"},{"key":"2024102103070625000_61.4.2102861.30","doi-asserted-by":"publisher","DOI":"10.1021\/bi060490t"},{"key":"2024102103070625000_61.4.2102861.31","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12392"},{"key":"2024102103070625000_61.4.2102861.32","doi-asserted-by":"crossref","first-page":"100832","DOI":"10.1016\/j.jbior.2021.100832","article-title":"Phagosome maturation in macrophages: eat, digest, adapt, and repeat","volume":"82","author":"Fountain","year":"2021","journal-title":"Adv Biol Regul"},{"key":"2024102103070625000_61.4.2102861.33","doi-asserted-by":"crossref","first-page":"819554","DOI":"10.3389\/fcimb.2022.819554","article-title":"CFTR modulators restore acidification of autophago-lysosomes and bacterial clearance in cystic fibrosis macrophages","volume":"12","author":"Badr","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2024102103070625000_61.4.2102861.34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2024102103070625000_61.4.2102861.35","doi-asserted-by":"crossref","first-page":"jcs237610","DOI":"10.1242\/jcs.237610","article-title":"Loss of Ca2+ entry via Orai-TRPC1 induces ER stress, initiating immune activation in macrophages","volume":"133","author":"Nascimento Da Conceicao","year":"2019","journal-title":"J Cell Sci"},{"key":"2024102103070625000_61.4.2102861.36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1164\/rccm.201510-1922OC","article-title":"Mutations of cystic fibrosis transmembrane conductance regulator gene cause a monocyte-selective adhesion deficiency","volume":"193","author":"Sorio","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103070625000_61.4.2102861.37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1462-5822.2011.01716.x","article-title":"The type VI secretion system of Burkholderia cenocepacia targets multiple Rho family GTPases disrupting the actin cytoskeleton and the assembly of NADPH oxidase complex in macrophages","volume":"14","author":"Rosales-Reyes","year":"2011","journal-title":"Cell Microbiol"},{"key":"2024102103070625000_61.4.2102861.38","doi-asserted-by":"crossref","first-page":"107721","DOI":"10.1016\/j.celrep.2020.107721","article-title":"Inactivation of Rho GTPases by Burkholderia cenocepacia induces a WASH-mediated actin polymerization that delays phagosome maturation","volume":"31","author":"Walpole","year":"2020","journal-title":"Cell Rep"},{"key":"2024102103070625000_61.4.2102861.39","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20294"},{"key":"2024102103070625000_61.4.2102861.40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jcf.2013.05.002","article-title":"Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis","volume":"12","author":"Paats","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2024102103070625000_61.4.2102861.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2004.03.006"},{"key":"2024102103070625000_61.4.2102861.42","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5HI1117-454RR"},{"key":"2024102103070625000_61.4.2102861.43","doi-asserted-by":"crossref","first-page":"e150239","DOI":"10.1172\/jci.insight.150239","article-title":"Recruitment and training of alveolar macrophages after pneumococcal pneumonia","volume":"7","author":"Arafa","year":"2022","journal-title":"JCI Insight"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02861-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:09:43Z","timestamp":1740380983000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02861-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1183\/13993003.02861-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02861-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}